Technologies

Diagnostic Assays

Diagnostic Assays Portfolios

Most Recent Inventions

Enhanced Endotoxin Detection: New Advantages in Liquid Crystal Assays for Gram-Negative Pathogens

UW–Madison researchers have now demonstrated enhanced endotoxin detection in the presence of masking agents in their previous liquid crystal system.

Unlike the LAL assay, the LC-based method does not suffer from LER or any loss of sensitivity due to the presence of cations (e.g., Ca2+ or Mg2+), buffers (e.g., citrate), surfactants (e.g., SDS), chelating agents (e.g., EDTA), proteins or nucleic acids (e.g., DNA or RNA). Thus, the LC-based method provides faster and cheaper detection of endotoxin when compared to existing methods, such as the LAL assay.
P160072WO01

Noninvasive Assay for Bovine Embryo Quality

UW–Madison researchers have identified 11 microRNAs (miRNAs) and 18 mRNAs as indicators of healthy IVF embryo development. They discovered that the miRNAs are differentially expressed between bovine blastocyst-stage embryos and those that fail to develop (‘degenerates’). This is the first report that miRNA levels in the culture medium differ among embryos of different developmental fate and can be used as indicators of embryo viability.
P150131US02

Predicting Glucoregulatory Dysfunction

UW–Madison researchers have developed a method based on blood lipid chemistry to identify a subject at risk for glucoregulatory dysfunction. The method involves obtaining a biosample from the subject, separating the diacylglycerol fatty acids and determining if the concentration is above or below a control range.
P150057US02

Blood Protein Biomarkers for Detection of Colon Cancer

UW–Madison researchers have developed methods and kits for diagnosing colon cancer, including precancerous and early stage disease, using protein biomarkers in blood/serum. Approximately 30 peptides identified and validated in animal models were used to conduct targeted proteomic analysis in humans. The serum levels of several of the biomarkers correlated with cancer incidence and outcomes in the study of normal patients versus those with stage 1, 2 or stage 3 colon cancer.
P150077US02

Assay to Determine Risk of Fungal Infection

More specifically, the researchers have developed a detection agent made up of calnexin peptides that recognize the telltale signs of infection. The peptides are able to track how a patient’s helper T cells respond to infection and/or vaccination.
P140236US02

Most Recent Patents

Biomarkers for Detecting Prostate Cancer

UW–Madison researchers have identified eight genetic markers, or biomarkers, for prostate cancer. They can be detected in histologically normal prostate samples and/or the bodily fluids of men with no history of prostate cancer.

The biomarkers act as red flags, exhibiting abnormal methylation levels when cancer is present in peripheral prostate tissue (this is called cancer ‘field defect’). These changes are believed to represent early stages of the cancer process.

The biomarkers are associated with the genes CAV1, EVX1, MCF2L, FGF1, WNT2, NCR2, EXT1 and SPAG4.
P130258US03

Field Test for Mycobacterial Infections

A UW–Madison researcher has identified a set of biomarkers that can indicate whether a mammal is vaccinated or infected, as well as the type of infection (bovine tuberculosis or Johne’s disease).
P150020US02

Diagnostic Kit for Blastomycosis

UW–Madison researchers have developed a method for obtaining highly pure native BAD-1 protein that could be used to detect B. dermatitidis infection.

A solution containing native BAD-1 protein or fragments is collected from cultured fungus strains. The solution is combined with nickel-chelating resin, washed and eluted to obtain a highly pure form without the need for more expensive recombinant methods. This can be mixed and analyzed with a patient’s sample to determine if the fungus is present.
P110280US02